New Low-Dose Ebola Monoclonal Antibody Offers Hope for Future Broad-Spectrum Filovirus Therapies
Monoclonal antibody 3A6 (mAb 3A6) is finding its way as a promising and powerful therapy protection against Ebola virus disease by targeting a conserved region of the Ebola glycoprotein. mAb 3A6 binds to a GP1,2 glycoprotein and “lifts” it away from the viral membrane, blocking the infection. In guinea pigs and rhesus monkeys with advanced Ebola infection and high viral loads, low dose mAb 3A6 treatment achieved complete survival and reversed disease symptoms. These findings could guide development of more effective, lower-cost Ebola therapies and broad-spectrum filovirus vaccines.










